Compare UG & ARAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UG | ARAY |
|---|---|---|
| Founded | 1942 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.5M | 31.3M |
| IPO Year | 1995 | 2006 |
| Metric | UG | ARAY |
|---|---|---|
| Price | $7.08 | $0.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 6.9K | ★ 397.6K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | ★ 7.10% | N/A |
| EPS Growth | N/A | ★ 87.50 |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $10,545,468.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.58 |
| P/E Ratio | $36.25 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.58 | $0.22 |
| 52 Week High | $8.45 | $2.10 |
| Indicator | UG | ARAY |
|---|---|---|
| Relative Strength Index (RSI) | 50.51 | 35.17 |
| Support Level | $6.90 | N/A |
| Resistance Level | $7.48 | $0.29 |
| Average True Range (ATR) | 0.19 | 0.02 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 35.35 | 5.98 |
United-Guardian Inc manufactures, markets and develops specialty cosmetic, personal care and sexual wellness ingredients, and a line of healthcare products including pharmaceuticals and medical lubricants. Its pharmaceutical products are distributed through national drug wholesalers to pharmacies, physicians, and hospitals. It operates in one business segment and its current product lines are separated into four distinct product categories that are cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. The company's majority of revenue is derived from the sales of Pharmaceuticals in the United States.
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention. The company has one operating segment which develops, manufactures and markets proprietary medical devices used in radiation therapy for the treatment of cancer patients.